// App-Quantinova.ai

OT3-17-01 : OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Researchers

Presenter

  • Robert C Stein

Principal Investigators

  • Andreas Makris

  • Luke Hughes-Davies

  • Iain R MacPherson

  • Carmel Conefrey

  • Leila Rooshenas

  • Sarah E Pinder

  • Abeer M Shaaban

  • Bjrn Naume

  • David A Cameron

  • Daniel W Rea

  • Helena M Earl

  • Christopher J Poole

  • Peter S Hall

  • Georgina Dotchin

  • Stuart A McIntosh

  • Victoria Harmer

  • Adrienne Morgan

  • Bethany Shinkins

  • Nigel Stallard

  • Christopher McCabe

  • Jenny L Donovan

  • John MS Bartlett

  • Janet A Dunn

Medical Centers

  • National Institute for Health Research University College London Hospitals BioMedical Research Centre, London, United Kingdom

  • Warwick Medical School, Univeristy of Warwick, Coventry, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

  • Population Health Sciences, University of Bristol, United Kingdom,

  • Kings College London, London, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Oslo University Hospital, Oslo, Norway

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

  • University of Cambridge, Department of Oncology and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom

  • University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • Imperial College, London, United Kingdom

  • Independent Cancer Patients Voice, Surrey, United Kingdom

  • Academic Unit of Health Economics, University of Leeds, Leeds, United Kingdom,

  • Institute of Health Economics and University of Alberta, Edmonton, AB, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

Locations

  • United Kingdom

  • Norway

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

  • Double Blind/Blinded

  • Non Inferiority

  • Prospective

Phase

  • NA

Study Id's

  • ISRCTN42400492

Sponsors

  • The Uk NIHR HTA Programme

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved